Skip to main content

Table 2 Associations with lytic/latent KSHV# seropositivity

From: Prevalence and predictors of kaposi sarcoma herpes virus seropositivity: a cross-sectional analysis of HIV-infected adults initiating ART in Johannesburg, South Africa

 

Overall KSHV#positive€

Positive to Lytic K8.1 only¥

Positive to Latent Orf 73 onlyβ

 

Total Positive

(n, %)

Adjusted PR# (95%CI)

Total Positive (n, %)

Adjusted PR#

(95%CI)

Total Positive

(n, %)

Adjusted PR# (95%CI)

Gender

      

   Female

127 (66%)

1

104 (66%)

1

73 (62%)

1

   Male

66 (34%)

0.96 (0.77-1.19)

54 (34%)

0.98 (0.75-1.26)

44 (38%)

1.16 (0.84-1.60)

Age category

      

   < 40 yrs.

118 (61%)

1

94 (59%)

1

69 (60%)

1

   ≥ 40 yrs.

75 (39%)

1.06 (0.86-1.31)

64 (41%)

1.00 (0.78-1.29)

48 (41%)

0.99 (0.73-1.35)

Language

      

   Zulu

43 (32%)

1

35 (33%)

1

29 (35%)

1

   Other

90 (68%)

1.21 (0.93-1.58)

71 (67%)

1.17 (0.84-1.62)

54 (65%)

1.09 (0.75-1.59)

Has tuberculosis

      

   No

160 (86%)

1

131 (87%)

1

97 (87%)

1

   Yes

25 (14%)

1.06 (0.78-1.42)

20 (13%)

1.08 (0.74-1.57)

15 (13%)

1.06 (0.67-1.67)

BMI category

      

   < 18.5

36 (21%)

1

28 (20%)

1

20 (19%)

1

   ≥ 18.5

137 79%)

1.28 (0.97-1.70)

114 (80%)

1.33 (0.94-1.90)

85 (81%)

1.46 (0.94-2.26)

Hemoglobin

      

   ≥ 8.5 g/dL

166 (89%)

1

136 (89%)

1

96 (85%)

1

   < 8.5 g/dL

21 (11%)

1.15 (0.84-1.56)

17 (11%)

1.17 (0.80-1.72)

17 (15%)

1.64 (1.11-2.43)

CD4 count

      

   0-50 cells

47 (28%)

1

39 (28%)

1

24 (23%)

1

   51-100 cells

39 (23%)

1.18 (0.87-1.62)

29 (21%)

1.03 (0.68-1.55)

28 (27%)

1.61 (0.97-2.66)

   101-200 cells

65 (38%)

1.28 (0.97-1.68)

53 (38%)

1.16 (0.75-1.81)

37 (36%)

1.29 (0.72-2.30)

   201-350 cells

19 (11%)

0.98 (0.65-1.47)

17 (12%)

0.96 (0.52-1.76)

15 (14%)

1.27 (0.59-2.90)

CD3 count

      

   < 500 cells

41 (21%)

1

34 (22%)

1

22 (19%)

1

   ≥ 500 cells

152 (79%)

1.35 (1.04-1.76)

124 (78%)

1.31 (0.93-1.84)

95 (81%)

1.62 (1.04-2.54)

CD8 count

      

   < 500 cells

64 (33%)

1

54 (34%)

1

35 (30%)

1

   ≥ 500 cells

129 (67%)

1.20 (0.96-1.50)

104 (66%)

1.09 (0.81-1.47)

82 (70%)

1.41 (0.96-2.09)

  1. # KSHV = Kaposi sarcoma herpes virus, PR = prevalence ratio estimated from log-binomial regression model. All models adjusted for sex, age and baseline CD4 count
  2. € KSHV negative individuals used as the comparison group
  3. ¥ Those who did not react to lytic K8.1 including the KSHV negative individuals used as the comparison group
  4. β Those who did not react to latent Orf73 including the KSHV negative individuals used as the comparison group
Back to article page

Infectious Agents and Cancer

ISSN: 1750-9378

Contact us